1-9 of 9
Nabeel Bardeesy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations

Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L. Norden, Ryan B. Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John Tyhonas, Matthew Lardy, Kathryn B. Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa S. Silveira, Nabeel Bardeesy
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2181–2192.
https://doi.org/10.1158/1078-0432.CCR-23-3588
Published: 15 May 2024
View articletitled, The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations
Open the PDF for The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations in another window
Includes: Supplementary data
Journal Articles

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

Qibiao Wu, Haley Ellis, Giulia Siravegna, Alexa G. Michel, Bryanna L. Norden, Ferran Fece de la Cruz, Eranga Roshan Balasooriya, Yuanli Zhen, Vanessa S. Silveira, Jianwe Che, Ryan B. Corcoran, Nabeel Bardeesy
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 198–208.
https://doi.org/10.1158/1078-0432.CCR-23-1317
Published: 05 January 2024
View articletitled, Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Open the PDF for Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential

Hiroyuki Kato, Haley Ellis, Nabeel Bardeesy
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4527–4529.
https://doi.org/10.1158/1078-0432.CCR-23-2221
Published: 14 November 2023
View articletitled, KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential
Open the PDF for KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential in another window
Journal Articles

Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI

Derek J. Erstad, Mozhdeh Sojoodi, Martin S. Taylor, Veronica Clavijo Jordan, Christian T. Farrar, Andrea L. Axtell, Nicholas J. Rotile, Chloe Jones, Katherine A. Graham-O'Regan, Diego S. Ferreira, Theodoros Michelakos, Filippos Kontos, Akhil Chawla, Shen Li, Sarani Ghoshal, Yin-Ching Iris Chen, Gunisha Arora, Valerie Humblet, Vikram Deshpande, Motaz Qadan, Nabeel Bardeesy, Cristina R. Ferrone, Michael Lanuti, Kenneth K. Tanabe, Peter Caravan, Bryan C. Fuchs
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 5007–5018.
https://doi.org/10.1158/1078-0432.CCR-18-1359
Published: 15 September 2020
View articletitled, Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI
Open the PDF for Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI in another window
Includes: Supplementary data
Journal Articles

No Cell Left Unturned: Intraductal Papillary Mucinous Neoplasm Heterogeneity

Yasmin G. Hernandez-Barco, Nabeel Bardeesy, David T. Ting
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2027–2029.
https://doi.org/10.1158/1078-0432.CCR-18-3877
Published: 01 April 2019
View articletitled, No Cell Left Unturned: Intraductal Papillary Mucinous Neoplasm Heterogeneity
Open the PDF for No Cell Left Unturned: Intraductal Papillary Mucinous Neoplasm Heterogeneity in another window
Journal Articles

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma

Francesco Sabbatino, Vincenzo Villani, Jennifer H. Yearley, Vikram Deshpande, Lei Cai, Ioannis T. Konstantinidis, Christina Moon, Sjoerd Nota, Yangyang Wang, Ahmad Al-Sukaini, Andrew X. Zhu, Lipika Goyal, David T. Ting, Nabeel Bardeesy, Theodore S. Hong, Carlos Fernandez-del Castillo, Kenneth K. Tanabe, Keith D. Lillemoe, Soldano Ferrone, Cristina R. Ferrone
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 470–478.
https://doi.org/10.1158/1078-0432.CCR-15-0715
Published: 14 January 2016
View articletitled, PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
Open the PDF for PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma

Agrin Moeini, Daniela Sia, Nabeel Bardeesy, Vincenzo Mazzaferro, Josep M. Llovet
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 291–300.
https://doi.org/10.1158/1078-0432.CCR-14-3296
Published: 14 January 2016
View articletitled, Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Open the PDF for Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma in another window
Journal Articles

Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer

Brinda Alagesan, Gianmarco Contino, Alexander R. Guimaraes, Ryan B. Corcoran, Vikram Deshpande, Gregory R. Wojtkiewicz, Aram F. Hezel, Kwok-Kin Wong, Massimo Loda, Ralph Weissleder, Cyril Benes, Jeffrey A. Engelman, Nabeel Bardeesy
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (2): 396–404.
https://doi.org/10.1158/1078-0432.CCR-14-1591
Published: 14 January 2015
View articletitled, Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
Open the PDF for Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Darrell R. Borger, Lipika Goyal, Thomas Yau, Ronnie T. Poon, Marek Ancukiewicz, Vikram Deshpande, David C. Christiani, Hannah M. Liebman, Hua Yang, Hyeryun Kim, Katharine Yen, Jason E. Faris, A. John Iafrate, Eunice L. Kwak, Jeffrey W. Clark, Jill N. Allen, Lawrence S. Blaszkowsky, Janet E. Murphy, Supriya K. Saha, Theodore S. Hong, Jennifer Y. Wo, Cristina R. Ferrone, Kenneth K. Tanabe, Nabeel Bardeesy, Kimberly S. Straley, Sam Agresta, David P. Schenkein, Leif W. Ellisen, David P. Ryan, Andrew X. Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1884–1890.
https://doi.org/10.1158/1078-0432.CCR-13-2649
Published: 31 March 2014
View articletitled, Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
Open the PDF for Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma in another window
Includes: Supplementary data